Introduction Under specific conditions, a weak lead stimulus, or “prepulse”, can inhibit the
startling effects of a subsequent intense abrupt stimulus. This startle-inhibiting effect of the …

The research of the glutamatergic system in schizophrenia has advanced with the use of
non-competitive antagonists of glutamate NMDA receptors (phencyclidine, ketamine, and …

Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported
to act as an agonist of the vanilloid 1 channel in the transient receptor potential family …

Abnormalities in glutamatergic signalling are proposed in schizophrenia in light of the
schizophreniform psychosis elicited by NMDA antagonists. The metabotropic glutamate …

Schizophrenia is a severe disorder characterized by positive, negative and cognitive
symptoms, which are still not fully understood. The development of efficient antipsychotics …

Cannabidiol is a non-psychoactive phytocannabinoid which, based on several previous
preclinical and clinical reports, is purported to have antipsychotic potential. The purpose of …

Schizophrenia is a severe mental illness characterized by positive and negative symptoms
and cognitive deficits. Reduction of glutamatergic neurotransmission by NMDA receptor …

The physical and functional interactions between serotonin–glutamate and serotonin–
dopamine signaling have been suggested to be involved in psychosis pathophysiology and …

Rationale Impaired cerebral glucose metabolism is a core pathological feature of
schizophrenia. We recently demonstrated that a ketogenic diet, causing a shift from …

Rationale l-Theanine (N-ethyl-l-glutamine) is an amino acid uniquely found in green tea and
historically considered to be a relaxing agent. It is a glutamate derivative and has an affinity …